Citicoline Supplement

## What it is Citicoline (cytidine 5'-diphosphocholine, also called CDP-choline) is a naturally occurring intermediate in the Kennedy pathway, the cellular synthesis route for phosphatidylcholine, the major phospholipid in neuronal membranes. The compound was first isolated and characterized in the 1950s by Eugene Kennedy at Harvard, whose work elucidated the lipid synthesis pathway that bears his name. Pharmaceutical development followed in Japan (Daiichi) and Italy (Cebrex/Ferrer) through the 1970s and 1980s. In most of the world citicoline is a prescription medication for stroke recovery, head injury rehabilitation, and vascular cognitive impairment. It is on the WHO essential medicines list in some configurations. The US is an exception: in 2009 Kyowa Hakko received GRAS notification for the branded form Cognizin, which has since become the dominant US supplement preparation. The supplement-form availability in the US sits alongside continued prescription availability in Europe, Latin America, and Asia. The mechanistic basis is dual. After oral absorption citicoline is hydrolyzed to cytidine and choline, both of which cross the blood-brain barrier and are then recombined intracellularly to reform CDP-choline within neurons. The cytidine and choline moieties contribute to phosphatidylcholine synthesis (membrane integrity and repair), while the choline component also feeds acetylcholine synthesis. The cytidine is metabolized to uridine in humans (unlike rodents where it remains as cytidine), and uridine has its own role in nucleotide and phospholipid synthesis. Legally citicoline is unscheduled. WADA does not list it. The supplement-form market in the US has grown substantially since the 2009 GRAS notification, and the Cognizin brand has accumulated a meaningful trial base in healthy-adult cognitive endpoints separate from the broader stroke-recovery literature. ## Mechanism of action The oral bioavailability is essentially complete: roughly 99% based on excretion studies. After absorption citicoline is hydrolyzed by intestinal and hepatic phosphatases to cytidine and choline. Both metabolites cross the blood-brain barrier and are recombined intracellularly via the rate-limiting enzyme CTP-phosphocholine cytidylyltransferase to reform CDP-choline within neurons. CDP-choline is a substrate for the final step of the Kennedy pathway, in which CDP-choline and diacylglycerol are combined to form phosphatidylcholine. Phosphatidylcholine is the major phospholipid in neuronal membranes, and its synthesis is partially substrate-limited in conditions of accelerated membrane turnover (stroke, head injury, neurodegeneration). The choline moiety also serves as substrate for acetylcholine synthesis. The acetylcholine contribution is similar in magnitude to alpha-GPC at equivalent total choline dose, although alpha-GPC delivers a larger choline payload per gram of compound. A distinct mechanism applies to the cytidine and uridine pathways. Uridine (the human metabolite of cytidine) supports synaptic membrane synthesis and is the basis for some of the neuroprotective signal observed in stroke and neurodegeneration models. The Wurtman group at MIT did extensive preclinical work documenting that uridine plus DHA plus choline produces synergistic membrane synthesis effects, which underpinned the development of medical foods like Souvenaid. Pharmacokinetics: oral bioavailability is roughly 99%. Peak plasma cytidine is reached at 1 hour after dosing; peak choline is reached at 2 to 3 hours. Plasma half-life of the cytidine-derived uridine is around 56 hours. The compound distributes broadly across tissues and crosses the blood-brain barrier as the cytidine and choline metabolites. ## Evidence base by outcome ### Stroke recovery The largest single trial is ICTUS (Davalos 2012, n=2,298 acute ischemic stroke patients, 2,000 mg/day for 6 weeks then 1,000 mg/day for 6 months). The primary endpoint of global recovery at 90 days was negative. Subgroup analyses showed possible benefit in patients with moderate stroke and in those not receiving thrombolytic therapy, but the overall trial outcome did not support routine use in modern stroke care with thrombolysis. Earlier meta-analyses (Saver 2008) of the pre-thrombolysis era had shown a 13% absolute increase in good outcomes; the ICTUS result substantially attenuated the consensus. ### Vascular cognitive impairment The Cohen 2003 and Alvarez-Sabin 2013 trials (combined n>1,000) reported sustained cognitive benefits at 1,000 mg/day for 6 to 12 months in patients with vascular cognitive impairment. Effect sizes are moderate on cognitive batteries. The European clinical use is anchored in this evidence base. ### Cognitive performance in healthy adults The Cognizin-funded trial base in healthy adults includes McGlade 2012 (n=60 adolescent women, 250 or 500 mg/day for 28 days), McGlade 2015 (n=75 healthy men, 250 or 500 mg/day for 28 days), and Bruce 2014 (acute single-dose imaging trial). These trials report small to moderate gains on attention, working memory, and impulsivity measures. Most are funded by Kyowa Hakko, which warrants standard caution about funding-source bias, but the trial designs are reasonable and the directional consistency is good. ### Glaucoma Citicoline has been studied as adjunct in glaucoma to support optic nerve health. The signal from Italian trials (Parisi, Roberti) is positive on visual evoked potentials and small visual field improvements over 4 to 24 months at 500 to 1,600 mg/day. The compound is part of standard glaucoma neuroprotection protocols in some Italian centers. ### Traumatic brain injury The COBRIT trial (Zafonte 2012, n=1,213 TBI patients, 2,000 mg/day for 90 days) was negative on the primary cognitive functional recovery endpoint. The signal in earlier smaller TBI trials had been positive, and the COBRIT result substantially reset expectations for routine TBI use. ### ADHD adjunct A few small trials have tested citicoline as adjunct in ADHD with mixed results. Effect sizes are small and the trial base is too thin to support routine use. ### Memory in older adults without dementia Cotroneo 2013 (n=349 elderly adults with memory complaints, 1,000 mg/day for 9 months) reported MMSE preservation versus untreated controls. The trial was open-label, which limits the strength of the conclusion, but the signal is consistent with the vascular cognitive impairment trials. ## Dosage and protocols The European prescription dose for stroke recovery is 1,000 to 2,000 mg/day. The vascular cognitive impairment dose is 500 to 1,000 mg/day. Most trials run treatment for 6 weeks to 12 months. The healthy-adult supplement dose is typically 250 to 500 mg/day. Single doses of 500 mg before cognitive effort are the protocol most often referenced in acute-effect framings. Doses above 1,000 mg/day in healthy adults have not been characterized in modern trials. No titration is required; full effect on the substrate-availability axis is reached on the first dose. The cognitive endpoints in vascular indications accrue over weeks to months and are not detectable from a single-dose trial. Food timing matters modestly. Bioavailability is similar with or without food, but most users find GI tolerance better with food. Morning or split morning-and-afternoon dosing is preferred over evening because of the long half-life of the uridine metabolite. No formal cycling is required. Long-term continuous use in European prescription practice is well documented across years rather than months. Supplement-form continuous use beyond 6 months in healthy adults has not been studied in modern formats but the safety record is reassuring. ## Side effects and safety GI side effects are the most common adverse event, reported in roughly 5 to 8% of users at 1,000 mg/day. Headache, restlessness, and insomnia (with evening dosing) appear at lower rates. Hypotension has been reported rarely at high doses. The TMAO concern that applies to alpha-GPC also applies in modified form to citicoline because of the choline moiety. The total choline contribution per gram of compound is smaller than alpha-GPC (roughly 18% versus 40%), so the effective TMAO load at equivalent supplement dose is smaller. Drug interactions are mostly mild. Concurrent use with anticholinergic medications partially antagonizes both. Concurrent use with cholinesterase inhibitors is generally well tolerated. The cytidine and uridine metabolites can theoretically interact with antimetabolite chemotherapy (5-fluorouracil and similar), although clinical reports are absent. Pregnancy: the compound has been used in pregnant women in some prescription contexts (stroke during pregnancy) without documented harm, but routine use in healthy pregnant women is not characterized. Choline is generally recommended in pregnancy, but the citicoline-specific dose-response is not established. The long-term safety record across decades of European prescription use in stroke patients is reassuring. The compound is generally regarded as low-risk at therapeutic doses, with the dominant safety question being the cardiovascular one (TMAO at chronic high doses). ## Stack interactions and timing Citicoline pairs naturally with omega-3 fatty acids (especially DHA) for combined membrane-synthesis support. The Souvenaid medical food (Fortasyn Connect) combines uridine, DHA, choline, B vitamins, and antioxidants on this rationale. The combined-product trials in early Alzheimer's disease (LipiDiDiet) reported modest cognitive preservation. Pairing with caffeine and L-theanine is common in nootropic stacks and has no obvious antagonism. Pairing with alpha-GPC produces overlapping rather than synergistic choline delivery; one or the other is usually sufficient. The critical interaction list is short: avoid concurrent use with strong anticholinergic medications (mutual antagonism) and exercise caution with cholinergic agents (additive but generally well tolerated). The cytidine pathway interaction with antimetabolite chemotherapy is theoretical but worth flagging in patients on those regimens. ## Practical notes The Cognizin brand is the most consistently dosed and tested US supplement form, with the FDA GRAS notification dating to 2009. Generic citicoline supplements vary more in dose accuracy and purity. The European prescription preparations (Somazina, Ceraxon) are pharmaceutical-grade and dose-accurate. Expect onset of subjective effects within 1 to 2 hours of oral dosing. The chronic effect on cognitive endpoints in vascular indications accrues over weeks to months. The healthy-adult cognitive effect at 250 to 500 mg/day is small and most consistent on attention and impulsivity measures. The honest framing for healthy-adult cognitive use: the trial base is one of the larger in the choline-supplement space, and the effects are real but modest. The stroke and TBI flagship trials (ICTUS, COBRIT) reset expectations downward in the acute clinical setting. The chronic vascular cognitive impairment use case remains the most evidence-supported indication.